Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021
16 avr. 2021 08h00 HE
|
Zogenix, Inc
Seizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and shorter recovery time when seizure did occur.Non-Seizure benefits most commonly noted...
Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference
08 avr. 2021 08h00 HE
|
Zogenix, Inc
EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen...
Zogenix to Participate in the Stifel 3rd Annual CNS Day
25 mars 2021 08h00 HE
|
Zogenix, Inc
EMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen...
Zogenix to Participate in the Raymond James Institutional Investors Conference
02 mars 2021 08h00 HE
|
Zogenix, Inc
EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
25 févr. 2021 16h01 HE
|
Zogenix, Inc
Positive momentum continues for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $8.1 million in the fourth quarter; total net sales of $9.6...
Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
18 févr. 2021 08h00 HE
|
Zogenix, Inc
EMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will...
Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
11 févr. 2021 08h00 HE
|
Zogenix, Inc
EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial...
Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome
01 févr. 2021 03h00 HE
|
Zogenix, Inc
FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental...
Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales
11 janv. 2021 08h00 HE
|
Zogenix, Inc
Total FINTEPLA® preliminary, unaudited net product sales of approximately $8.1 million for the fourth quarterAs of December 31, 2020, 492 healthcare prescribers had completed FINTEPLA Risk Evaluation...
The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome
21 déc. 2020 08h00 HE
|
Zogenix, Inc
Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancyEC approval is based on Phase 3 study data demonstrating that FINTEPLA safely and significantly...